Yıl: 2021 Cilt: 3 Sayı: 1 Sayfa Aralığı: 22 - 30 Metin Dili: İngilizce DOI: 10.36519/idcm.2021.40 İndeks Tarihi: 03-10-2021

Persistent Symptoms After Discharge ofCOVID-19 patients

Öz:
Objective: Many observational studies have reported high morbidity and mortality associated with COVID-19 during hospitalisation. This study aimed to examine the longterm symptoms and related factors of patients hospitalised due to COVID-19.Materials and Methods: Clinical and laboratory characteristics of 266 patients who were followed up in the hospital with the diagnosis of COVID-19 were recorded. The patients were followed for an average of 14 weeks after discharge. The discharged patients were surveyed for their symptoms by calling.Results: On average, 14 weeks after being discharged, it was found that a least one symptom persisted in 27.4% (n =73) of 266 patients. The three most common symptoms after discharge were 38.3% (n = 28) cough, headache (36.9%, n = 27), shortness of breath (27.3%, n = 20), respectively. In multivariate analysis, it was found that symptoms persist more in patients with high CRP (C-reactive protein) and ferritin during hospitalisation (p: 0.03; p: 0.005, respectively). Conclusion: After COVID-19, it was observed that complaints continued after discharge in a significant number of patients. During hospitalisation, high ferritin and CRP levels were found to be associated with the persistence of symptoms. It was considered that symptoms associated with COVID-19 persist more in those with a high inflammatory response.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
  • 1 World HealthCenters for Disease Control and Prevention (CDC). Long-Term Effects of COVID-19. 2020 Nov 13 (cited 2021 January 11). Available from: https://www.cdc.gov/coronavirus/2019-ncov/ long-term-effects.html.
  • 2 National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2020 Dec 18 (cited 2021 January 11). Available from: https://www.nice.org.uk/guidance/NG188.
  • 3 Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020; 6: 00542-2020.
  • 4 World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance. 2020 March 20 (cited 2021 January 11). Available from: https://apps.who.int/iris/handle/10665/331506. 2020.
  • 5 Magnus P, Gunnes N, Tveito K, Bakken IJ, Ghaderi S, Stoltenberg C, et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine 2015; 33: 6173-7.
  • 6 Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011; 11: 37.
  • 7 Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220-32.
  • 8 Galal I, Hussein AARM, Amin MT, Saad MM, Zayan HEE, Abdelsayed MZ, et al. Determinants of persistent post COVID-19 symptoms: value of a novel COVID-19 symptoms score. Medrxiv 2020. 11.11.20230052
  • 9 Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. Int Immunol 2017; 29: 401–9.
  • 10 Rosário C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013; 11: 185.
  • 11 Lalueza A, Ayuso B, Arrieta E, Trujillo H, Folgueira D, Cueto C, et al. Elevation of serum ferritin levels for predicting a poor outcome in hospitalized patients with influenza infection. Clin Microbiol Infect 2020; 26: 1557.e9-1557.e15
  • 12 Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis 2020; 14:1753466620937175.
  • 13 Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev 2020; 53: 38-42.
  • 14 Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020: 1-8.
  • 15 Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 2021; 27 :258-63.
  • 16 Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049-6057. doi:10.18632/aging.103000
APA evlice o, Kuş F, BEKTAS M (2021). Persistent Symptoms After Discharge ofCOVID-19 patients. , 22 - 30. 10.36519/idcm.2021.40
Chicago evlice oğuz,Kuş Fatih,BEKTAS MURAT Persistent Symptoms After Discharge ofCOVID-19 patients. (2021): 22 - 30. 10.36519/idcm.2021.40
MLA evlice oğuz,Kuş Fatih,BEKTAS MURAT Persistent Symptoms After Discharge ofCOVID-19 patients. , 2021, ss.22 - 30. 10.36519/idcm.2021.40
AMA evlice o,Kuş F,BEKTAS M Persistent Symptoms After Discharge ofCOVID-19 patients. . 2021; 22 - 30. 10.36519/idcm.2021.40
Vancouver evlice o,Kuş F,BEKTAS M Persistent Symptoms After Discharge ofCOVID-19 patients. . 2021; 22 - 30. 10.36519/idcm.2021.40
IEEE evlice o,Kuş F,BEKTAS M "Persistent Symptoms After Discharge ofCOVID-19 patients." , ss.22 - 30, 2021. 10.36519/idcm.2021.40
ISNAD evlice, oğuz vd. "Persistent Symptoms After Discharge ofCOVID-19 patients". (2021), 22-30. https://doi.org/10.36519/idcm.2021.40
APA evlice o, Kuş F, BEKTAS M (2021). Persistent Symptoms After Discharge ofCOVID-19 patients. Infectious diseases and clinical microbiology (Online), 3(1), 22 - 30. 10.36519/idcm.2021.40
Chicago evlice oğuz,Kuş Fatih,BEKTAS MURAT Persistent Symptoms After Discharge ofCOVID-19 patients. Infectious diseases and clinical microbiology (Online) 3, no.1 (2021): 22 - 30. 10.36519/idcm.2021.40
MLA evlice oğuz,Kuş Fatih,BEKTAS MURAT Persistent Symptoms After Discharge ofCOVID-19 patients. Infectious diseases and clinical microbiology (Online), vol.3, no.1, 2021, ss.22 - 30. 10.36519/idcm.2021.40
AMA evlice o,Kuş F,BEKTAS M Persistent Symptoms After Discharge ofCOVID-19 patients. Infectious diseases and clinical microbiology (Online). 2021; 3(1): 22 - 30. 10.36519/idcm.2021.40
Vancouver evlice o,Kuş F,BEKTAS M Persistent Symptoms After Discharge ofCOVID-19 patients. Infectious diseases and clinical microbiology (Online). 2021; 3(1): 22 - 30. 10.36519/idcm.2021.40
IEEE evlice o,Kuş F,BEKTAS M "Persistent Symptoms After Discharge ofCOVID-19 patients." Infectious diseases and clinical microbiology (Online), 3, ss.22 - 30, 2021. 10.36519/idcm.2021.40
ISNAD evlice, oğuz vd. "Persistent Symptoms After Discharge ofCOVID-19 patients". Infectious diseases and clinical microbiology (Online) 3/1 (2021), 22-30. https://doi.org/10.36519/idcm.2021.40